REVOLUTION Clinical Study

Title:Randomized, Blinded, Controlled Trial to EValuate the EcOnomic and ClinicaL Outcomes of Utilizing Genetic Testing to Improve Therapeutic Decision-Making COmpared to Empiric Prescribing as the StaNdard of Care (REVOLUTION Study)”

Study Sponsor: Proove Medical Laboratories, Inc.

Principal Investigator: Christopher Rumana,MD

Study Synopsis: The objective of this study is to provide individualized medical management of several common conditions (pain, arthritis, mental health, type 2 diabetes, and cardiovascular disease) using genotype analysis to analyze predisposition to adverse drug events, co-morbidities, disease severity or age of onset, and drug metabolism.

Eligible patients are candidates for pharmaceutical interventions to deal with the five common medical conditions. Enrolled patients will submit a DNA sample via cheek swab and be randomized to either Intervention group (Group A) or Control group (Group B). Patients will be required to complete study assessments at each study visit from baseline, 30 days, and 60 days post enrollment.

Study Status: Open to Enrollment.

For more information, contact Lutheria Hollis, CCRC at (850) 201-2350

Call Us (850) 877-5115